AR089011A1 - 2h-indazoles como antagonistas del receptor ep₂ - Google Patents
2h-indazoles como antagonistas del receptor ep₂Info
- Publication number
- AR089011A1 AR089011A1 ARP120104465A ARP120104465A AR089011A1 AR 089011 A1 AR089011 A1 AR 089011A1 AR P120104465 A ARP120104465 A AR P120104465A AR P120104465 A ARP120104465 A AR P120104465A AR 089011 A1 AR089011 A1 AR 089011A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- residue
- cycloalkyl
- membered
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
Abstract
La presente se refiere a 2H-indazoles de la fórmula general (1), métodos para su preparación y su uso para la producción de agentes farmacéuticos para el tratamiento de enfermedades e indicaciones que están ligadas con el receptor de EP₂, enfermedades relativas a la biología reproductiva femenina (menorragia, dismenorrea, endometriosis, procesos neurodegenerativos, etc.). Reivindicación 1: Compuestos de la fórmula general (1) en donde R¹: significa H, alquilo C₁₋₂ o alquil C₁₋₂-oxi; R²: es H o metilo; siempre que uno de los dos residuos R¹ o R² sea H; X: es -(CH₂)ₗ-, -(CH₂)ₖ-O-, -CH₂-S-, CH₂-S(O)₂-, -CH(CH₃)-, -CH(CH₃)-O- o -C(CH₃)₂-O-; k: es 1 ó 2; I: es 0, 1 ó 2; R⁴: H, alquilo C₁₋₄, cicloalquilo C₃₋₄ o CH₂-cicloalquilo C₃₋₄; y el caso de que X: -CH₂- o -CH(CH₃)- R⁴: significa adicionalmente un residuo de heterociclilo de 4 - 6 miembros; el caso de que X: -(CH₂)ₗ- o -CH(CH₃)- R⁴: significa adicionalmente CN; o X junto con R⁴ forman un residuo de heterociclilo de 4 - 6 miembros por medio de una ligación de carbono de anillo; m: es 1 ó 2; n: es 1 ó 2; Ar: es un residuo de arilo de 6 - 10 miembros o residuo de hetarilo de 5 - 10 miembros, R³: es halógeno, CN, SF₅, alquilo C₁₋₄, cicloalquilo C₃₋₆, heterociclilo C₄₋₆, O-alquilo C₁₋₄, O-cicloalquilo C₃₋₆, O-heterociclilo C₄₋₆, S-alquilo C₁₋₄, S(O)₂-alquilo C₁₋₄, Ar, O-Ar, C(CH₃)₂-CN o C(CH₃)₂-OH; y Ar: un residuo de arilo de 6 miembros o residuo de heteroarilo de 5 - 6 miembros opcionalmente mono- o disustituido; en donde los sustituyentes están seleccionados de F, Cl, CN, alquilo C₁₋₄, O-alquilo C₁₋₄, C₍CH₃)₂-CN, C(CH₃)₂-OH y C(O)NH₂; y sus isómeros, diastereómeros, enantiómeros y sales o clatratos de ciclodextrina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011087170 | 2011-11-28 | ||
DE102012206715 | 2012-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089011A1 true AR089011A1 (es) | 2014-07-23 |
Family
ID=47278803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104465A Pending AR089011A1 (es) | 2011-11-28 | 2012-11-28 | 2h-indazoles como antagonistas del receptor ep₂ |
Country Status (25)
Country | Link |
---|---|
US (1) | US9062041B2 (es) |
EP (1) | EP2785707B1 (es) |
JP (1) | JP6192654B2 (es) |
KR (1) | KR20140103984A (es) |
CN (1) | CN104144922B (es) |
AR (1) | AR089011A1 (es) |
AU (1) | AU2012344015A1 (es) |
BR (1) | BR112014012459A2 (es) |
CA (1) | CA2856769A1 (es) |
CL (1) | CL2014001392A1 (es) |
CO (1) | CO6970595A2 (es) |
CR (1) | CR20140257A (es) |
DO (1) | DOP2014000114A (es) |
EA (1) | EA201400623A1 (es) |
EC (1) | ECSP14002542A (es) |
ES (1) | ES2665510T3 (es) |
HK (1) | HK1203938A1 (es) |
IL (1) | IL232503A (es) |
IN (1) | IN2014CN03854A (es) |
MX (1) | MX2014006433A (es) |
PE (1) | PE20141579A1 (es) |
PH (1) | PH12014501195A1 (es) |
SG (1) | SG11201402269RA (es) |
TW (1) | TW201326154A (es) |
WO (1) | WO2013079425A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2755944B1 (en) | 2011-09-16 | 2017-06-14 | Sanofi | Biarylderivatives,their preparation and their therapeutic application |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
WO2014187744A1 (de) * | 2013-05-23 | 2014-11-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen („on-demand") kontrazeption |
WO2014187793A1 (de) * | 2013-05-23 | 2014-11-27 | Bayer Pharma Aktiengesellschaft | Verwendung einer pharmazeutischen zusammensetzung zur notfallkontrazeption |
EP3151820A4 (en) | 2014-06-06 | 2017-11-22 | Flexus Biosciences, Inc. | Immunoregulatory agents |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
EA201790806A1 (ru) | 2014-11-05 | 2017-11-30 | Флексус Байосайенсиз, Инк. | Иммунорегулирующие средства |
AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
JP2022506850A (ja) | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
WO2022138792A1 (ja) * | 2020-12-24 | 2022-06-30 | 小野薬品工業株式会社 | Ep2拮抗活性を有する化合物の塩、溶媒和物および結晶 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
EE03680B1 (et) | 1996-07-18 | 2002-04-15 | Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. | Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid |
HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
CA2457468A1 (en) | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient |
WO2003030911A1 (en) | 2001-10-08 | 2003-04-17 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
EP1439837B1 (en) | 2001-10-23 | 2008-04-09 | Laboratoires Serono SA | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
ATE371454T1 (de) | 2001-10-31 | 2007-09-15 | Medical Res Council | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie |
IL162602A0 (en) | 2001-12-20 | 2005-11-20 | Applied Research Systems | Pyrrolidine derivatives as prostaglandin modulators |
AP2004003094A0 (en) | 2002-01-31 | 2004-09-30 | Pfizer Prod Inc | Metabolities of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid |
NZ535024A (en) | 2002-03-05 | 2006-10-27 | Ono Pharmaceutical Co | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient |
US20060128810A1 (en) | 2002-10-10 | 2006-06-15 | Kyoto University | Remedies for allergic diseases |
DK1866292T3 (da) | 2005-03-31 | 2011-05-09 | Auckland Uniservices Ltd | Tricykliske 1,2,4-triazinoxider og sammensætninger deraf til terapeutisk anvendelse i cancerbehandlinger |
PL1816121T3 (pl) | 2005-11-21 | 2008-08-29 | Bayer Schering Pharma Ag | Pochodne 9-chloro-15-deoksyprostaglandyny, sposób ich wytwarzania oraz ich zastosowanie jako leków |
DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
WO2007091107A1 (en) | 2006-02-10 | 2007-08-16 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
EP1884906A1 (de) | 2006-07-31 | 2008-02-06 | Siemens Building Technologies Fire & Security Products GmbH & Co. oHG | Levelsynchronisation bei Funk-Kommunikationsnetzwerken |
EP1903037A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors |
EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
EP1903038A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
JP2010511721A (ja) | 2006-12-05 | 2010-04-15 | ナショナル チャオ トン ユニバーシティ | インダゾール化合物 |
KR20100009582A (ko) | 2007-05-10 | 2010-01-27 | 화이자 리미티드 | 아제티딘 유도체 및 프로스타글란딘 e2 길항제로서 그의 용도 |
EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
EP2002834A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
EP2003119A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Acetamide als Modulatoren des EP2-Rezeptors |
EP2014663A1 (de) | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
EP2014662A1 (de) | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors |
EP2222665A1 (en) * | 2007-11-15 | 2010-09-01 | Pfizer Limited | Azetidines as ep2 antagonists |
JP5375824B2 (ja) * | 2008-05-14 | 2013-12-25 | アステラス製薬株式会社 | アミド化合物 |
WO2010008777A2 (en) | 2008-06-23 | 2010-01-21 | Ligand Pharmaceuticals Inc. | Fused azabicyclic pyridines |
AP2011005728A0 (en) | 2008-11-10 | 2011-06-30 | Pfizer Ltd | Pyrrolidines. |
JP2012512877A (ja) * | 2008-12-18 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | セロトニン5−ht2b受容体阻害剤 |
TW201107315A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
DE102009049662A1 (de) * | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
-
2012
- 2012-11-16 TW TW101142970A patent/TW201326154A/zh unknown
- 2012-11-26 US US14/361,213 patent/US9062041B2/en not_active Expired - Fee Related
- 2012-11-26 MX MX2014006433A patent/MX2014006433A/es not_active Application Discontinuation
- 2012-11-26 KR KR1020147017230A patent/KR20140103984A/ko not_active Application Discontinuation
- 2012-11-26 CA CA2856769A patent/CA2856769A1/en not_active Abandoned
- 2012-11-26 AU AU2012344015A patent/AU2012344015A1/en not_active Abandoned
- 2012-11-26 WO PCT/EP2012/073556 patent/WO2013079425A1/en active Application Filing
- 2012-11-26 IN IN3854CHN2014 patent/IN2014CN03854A/en unknown
- 2012-11-26 PE PE2014000760A patent/PE20141579A1/es not_active Application Discontinuation
- 2012-11-26 ES ES12794931.1T patent/ES2665510T3/es active Active
- 2012-11-26 JP JP2014542872A patent/JP6192654B2/ja not_active Expired - Fee Related
- 2012-11-26 BR BR112014012459A patent/BR112014012459A2/pt active Search and Examination
- 2012-11-26 CN CN201280067965.1A patent/CN104144922B/zh not_active Expired - Fee Related
- 2012-11-26 EA EA201400623A patent/EA201400623A1/ru unknown
- 2012-11-26 EP EP12794931.1A patent/EP2785707B1/en not_active Not-in-force
- 2012-11-26 SG SG11201402269RA patent/SG11201402269RA/en unknown
- 2012-11-28 AR ARP120104465A patent/AR089011A1/es active Pending
-
2014
- 2014-05-08 IL IL232503A patent/IL232503A/en not_active IP Right Cessation
- 2014-05-27 PH PH12014501195A patent/PH12014501195A1/en unknown
- 2014-05-27 CL CL2014001392A patent/CL2014001392A1/es unknown
- 2014-05-28 DO DO2014000114A patent/DOP2014000114A/es unknown
- 2014-05-28 EC ECIEPI20142542A patent/ECSP14002542A/es unknown
- 2014-05-28 CR CR20140257A patent/CR20140257A/es unknown
- 2014-05-28 CO CO14115091A patent/CO6970595A2/es unknown
-
2015
- 2015-05-07 HK HK15104364.3A patent/HK1203938A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL232503A (en) | 2015-08-31 |
CA2856769A1 (en) | 2013-06-06 |
ES2665510T3 (es) | 2018-04-26 |
EP2785707A1 (en) | 2014-10-08 |
DOP2014000114A (es) | 2014-07-15 |
CN104144922A (zh) | 2014-11-12 |
PH12014501195A1 (en) | 2014-09-01 |
CR20140257A (es) | 2014-07-15 |
WO2013079425A1 (en) | 2013-06-06 |
EP2785707B1 (en) | 2018-01-24 |
MX2014006433A (es) | 2014-07-11 |
IL232503A0 (en) | 2014-07-01 |
AU2012344015A1 (en) | 2014-05-29 |
KR20140103984A (ko) | 2014-08-27 |
SG11201402269RA (en) | 2014-09-26 |
PE20141579A1 (es) | 2014-11-15 |
CO6970595A2 (es) | 2014-06-13 |
JP2014533713A (ja) | 2014-12-15 |
TW201326154A (zh) | 2013-07-01 |
JP6192654B2 (ja) | 2017-09-06 |
NZ624722A (en) | 2016-08-26 |
HK1203938A1 (en) | 2015-11-06 |
IN2014CN03854A (es) | 2015-09-04 |
CL2014001392A1 (es) | 2014-10-03 |
ECSP14002542A (es) | 2015-12-31 |
US20140336172A1 (en) | 2014-11-13 |
US9062041B2 (en) | 2015-06-23 |
BR112014012459A2 (pt) | 2017-06-06 |
CN104144922B (zh) | 2016-08-31 |
EA201400623A1 (ru) | 2014-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089011A1 (es) | 2h-indazoles como antagonistas del receptor ep₂ | |
CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
CY1119422T1 (el) | Παραγωγα μπετουλινης | |
EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
EA201992183A2 (ru) | Синтез полициклических карбамоилпиридоновых соединений | |
CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
CR20140548A (es) | Derivados de aril-sultamo como moduladores de rorc | |
CO7170131A2 (es) | Compuestos de heterociclilo | |
ECSP13012426A (es) | Promotores de apoptosis de n-acilsulfonamidas | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
CR20150061A (es) | Compuesto de pirazolopirimidinas | |
EA201591815A1 (ru) | Бицикло [2.2.2] кислоты - модуляторы gpr120 | |
EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
CY1125355T1 (el) | Πεντακυκλικη ενωση | |
CL2017001130A1 (es) | Síntesis de copanlisib y su sal diclorhidrato | |
GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
TW201613603A (en) | Pharmaceutical preparation | |
UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
CU20150006A7 (es) | Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato útiles como antagonistas del receptor -h3 | |
DOP2014000177A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 | |
CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
CY1122334T1 (el) | Νεες κρυσταλλικες mopφeς του αλατος μονονατριου της φορμασουλφουρονης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |